175 related articles for article (PubMed ID: 37553873)
1. Population modeling of bosutinib exposure-response in patients with newly diagnosed chronic phase chronic myeloid leukemia.
Garrett M; Knight B; Cortes JE; Deininger MW
Cancer Med; 2023 Sep; 12(17):17981-17992. PubMed ID: 37553873
[TBL] [Abstract][Full Text] [Related]
2. Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study.
Ono T; Hino M; Matsumura I; Fujisawa S; Ishizawa K; Sakaida E; Sekiguchi N; Ono C; Aizawa M; Tanetsugu Y; Koide Y; Takahashi N
Int J Hematol; 2022 Dec; 116(6):871-882. PubMed ID: 35963986
[TBL] [Abstract][Full Text] [Related]
3. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.
Cortes JE; Kim DW; Kantarjian HM; Brümmendorf TH; Dyagil I; Griskevicius L; Malhotra H; Powell C; Gogat K; Countouriotis AM; Gambacorti-Passerini C
J Clin Oncol; 2012 Oct; 30(28):3486-92. PubMed ID: 22949154
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia.
Hino M; Matsumura I; Fujisawa S; Ishizawa K; Ono T; Sakaida E; Sekiguchi N; Tanetsugu Y; Fukuhara K; Ohkura M; Koide Y; Takahashi N
Int J Hematol; 2020 Jul; 112(1):24-32. PubMed ID: 32279228
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia.
Cortes JE; Gambacorti-Passerini C; Deininger MW; Mauro MJ; Chuah C; Kim DW; Milojkovic D; le Coutre P; Garcia-Gutierrez V; Crescenzo R; Mamolo C; Reisman A; Hochhaus A; Brümmendorf TH;
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1589-1599. PubMed ID: 30989330
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial.
Chuah C; Koh LP; Numbenjapon T; Zang DY; Ong KH; Do YR; Ohkura M; Ono C; Viqueira A; Cortes JE; Brümmendorf TH
Int J Hematol; 2021 Jul; 114(1):65-78. PubMed ID: 33851349
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic-pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia.
Hsyu PH; Mould DR; Upton RN; Amantea M
Cancer Chemother Pharmacol; 2013 Jan; 71(1):209-18. PubMed ID: 23070145
[TBL] [Abstract][Full Text] [Related]
8. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study.
Hochhaus A; Gambacorti-Passerini C; Abboud C; Gjertsen BT; Brümmendorf TH; Smith BD; Ernst T; Giraldo-Castellano P; Olsson-Strömberg U; Saussele S; Bardy-Bouxin N; Viqueira A; Leip E; Russell-Smith TA; Leone J; Rosti G; Watts J; Giles FJ;
Leukemia; 2020 Aug; 34(8):2125-2137. PubMed ID: 32572189
[TBL] [Abstract][Full Text] [Related]
9. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial.
Brümmendorf TH; Cortes JE; Milojkovic D; Gambacorti-Passerini C; Clark RE; le Coutre P; Garcia-Gutierrez V; Chuah C; Kota V; Lipton JH; Rousselot P; Mauro MJ; Hochhaus A; Hurtado Monroy R; Leip E; Purcell S; Yver A; Viqueira A; Deininger MW;
Leukemia; 2022 Jul; 36(7):1825-1833. PubMed ID: 35643868
[TBL] [Abstract][Full Text] [Related]
10. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia.
Gambacorti-Passerini C; Cortes JE; Lipton JH; Dmoszynska A; Wong RS; Rossiev V; Pavlov D; Gogat Marchant K; Duvillié L; Khattry N; Kantarjian HM; Brümmendorf TH
Am J Hematol; 2014 Oct; 89(10):947-53. PubMed ID: 24944159
[TBL] [Abstract][Full Text] [Related]
11. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
Zwaan CM; Rizzari C; Mechinaud F; Lancaster DL; Lehrnbecher T; van der Velden VH; Beverloo BB; den Boer ML; Pieters R; Reinhardt D; Dworzak M; Rosenberg J; Manos G; Agrawal S; Strauss L; Baruchel A; Kearns PR
J Clin Oncol; 2013 Jul; 31(19):2460-8. PubMed ID: 23715577
[TBL] [Abstract][Full Text] [Related]
12. Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.
Yun S; Vincelette ND; Segar JM; Dong Y; Shen Y; Kim DW; Abraham I
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e85-94. PubMed ID: 27101984
[TBL] [Abstract][Full Text] [Related]
13. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
14. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).
Kantarjian HM; Shah NP; Cortes JE; Baccarani M; Agarwal MB; Undurraga MS; Wang J; Ipiña JJ; Kim DW; Ogura M; Pavlovsky C; Junghanss C; Milone JH; Nicolini FE; Robak T; Van Droogenbroeck J; Vellenga E; Bradley-Garelik MB; Zhu C; Hochhaus A
Blood; 2012 Feb; 119(5):1123-9. PubMed ID: 22160483
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome‒positive leukemias.
Kota V; Brümmendorf TH; Gambacorti-Passerini C; Lipton JH; Kim DW; An F; Leip E; Crescenzo RJ; Ferdinand R; Cortes JE
Leuk Res; 2021 Dec; 111():106690. PubMed ID: 34673442
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients.
García-Gutiérrez V; Milojkovic D; Hernandez-Boluda JC; Claudiani S; Martin Mateos ML; Casado-Montero LF; González G; Jimenez-Velasco A; Boque C; Martinez-Trillos A; Vázquez IM; Payer ÁR; Senín A; Amustio Díez E; García AB; Carrascosa GB; Ortí G; Ruiz BC; Fernández MÁ; Del Carmen García Garay M; Giraldo P; Guinea JM; De Las Heras Rodríguez N; Hernán N; Pérez AI; Piris-Villaespesa M; Lorenzo JLL; Martí-Tutusaus JMM; Vallansot RO; Ortega Rivas F; Puerta JM; Ramirez MJ; Romero E; Romo A; Rosell A; Saavedra SS; Sebrango A; Tallon J; Valencia S; Portero A; Steegmann JL;
Ann Hematol; 2019 Feb; 98(2):321-330. PubMed ID: 30446802
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study.
Gambacorti-Passerini C; Cortes JE; Lipton JH; Kantarjian HM; Kim DW; Schafhausen P; Crescenzo R; Bardy-Bouxin N; Shapiro M; Noonan K; Leip E; DeAnnuntis L; Brümmendorf TH; Khoury HJ
Haematologica; 2018 Aug; 103(8):1298-1307. PubMed ID: 29773593
[TBL] [Abstract][Full Text] [Related]
18. An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia.
Muresan B; Mamolo C; Cappelleri JC; Leip E; Viqueira A; Heeg B
Curr Med Res Opin; 2021 May; 37(5):801-809. PubMed ID: 33733983
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Generic Dasatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: A Multicenter Prospective Study in China.
Yu W; Du X; Wang W; Lou J; Liu P; Meng L; Jin J
Clin Lymphoma Myeloma Leuk; 2022 Sep; 22(9):e867-e873. PubMed ID: 35842355
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up.
Fujisawa S; Nakamae H; Ogura M; Ishizawa K; Taniwaki M; Utsunomiya A; Matsue K; Takamatsu Y; Usuki K; Tanimoto M; Ishida Y; Akiyama H; Onishi S
Int J Hematol; 2014 Feb; 99(2):141-53. PubMed ID: 24357015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
